Quote:

---

In rereading the trial design and exclusion criteria there doesn’t appear to be anything tying participation to the beginning of disease, but rather to baseline symptoms. If their symptoms meet the criteria and there are no exclusion issues, it seems like being 20+ days from when they were diagnosed wouldn’t/doesn’t matter. Perhaps that’s how they are getting in.

---

That's a really interesting theory. However, I wonder two things:

1. The P2 M/M trial is concluded -- so how could anyone be enrolled for this indication?

2. I would imagine this post-COVID type of treatment might skew the results of the trial in an unfavorable manner because it is testing the effect of the molecule on lingering symptoms which might be caused drivers that may be different from the ones related to the original infection.